Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rosalie V. Douglas
Observed names:
R. Douglas,
R.V. Douglas,
Rosalie Douglas
Institutions:
Belfast Health and Social Care Trust,
The Northern Ireland Cancer Centre
Observed institutions:
Queen's University Belfast,
Belfast Health and Social Care Trust,
Belfast City Hospital,
The Northern Ireland Cancer Centre
ORCID:
0009-0001-7493-0580
Observed ORCID:
0009-0001-7493-0580
OpenAlex ID:
A5061602220
Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom
2023
·
Jonathan L. Moore
, Michael Green
, et al.
·
Journal of Clinical Oncology
·
39
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
2019
·
Richard C Turkington
, Laura A Knight
, et al.
·
Gut
·
28
PDF
Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma
2024
·
Leanne Stevenson
, Lauren Cairns
, et al.
·
Scientific Reports
·
7
PDF
Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.
2024
·
Andy Cheng
, Suzanne Frank
, et al.
·
Journal of Clinical Oncology
·
7
Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches
2022
·
Niamh H. McCabe
, Leanne Stevenson
, et al.
·
Cancers
·
4
PDF
Abstract PO3-17-12: Safety and efficacy of Atezolizumab in combination with nab-Paclitaxel in patients with PD-L1 positive metastatic or locally advanced triple-negative breast cancer: A pan-UK cancer centre experience
2024
·
Jasmin V Waterhouse
, Alexandra Holdich
, et al.
·
Cancer Research
·
2
Safety and Efficacy of Atezolizumab in Combination With nab-Paclitaxel in Patients With PD-L1 Positive Metastatic or Locally Advanced Triple-Negative Breast Cancer: A UK-Wide Cancer Centre Experience
2025
·
J.V. Waterhouse
, A. Holdich
, et al.
·
Clinical Oncology
·
1
Targeting of survivin to overcome cisplatin resistance in esophageal adenocarcinoma.
2019
·
Rosalie V. Douglas
, Leanne Stevenson
, et al.
·
Journal of Clinical Oncology
·
1
AXL Mediates Resistance to AKT inhibition in Oesophageal Adenocarcinoma.
2017
·
Richard Turkington
, Lauren Cairns
, et al.
·
1
PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.
2017
·
Eileen E. Parkes
, Jaine K. Blayney
, et al.
·
Journal of Clinical Oncology
·
1
Identification of targetable mediators of resistance to chemotherapy in oesophageal adenocarcinoma
2026
·
Rosalie Douglas
·
Research Portal (Queen's University Belfast)
Efficacy and safety of Anthracycline versus Non-Anthracycline Neoadjuvant Chemotherapy in HER2 positive Early Breast Cancer: A retrospective study in Northern Ireland
2026
·
Eva Urbankova
, Hebaallah Elsandoby
, et al.
·
Clinical Oncology
Abstract PS3-09-13: Adjuvant Abemaciclib in Male Breast Cancer: A UK Multicentre Case Series from the CONCISE Study
2026
·
A. Ghose
, H. Abdallah
, et al.
·
Clinical Cancer Research
Abstract PS2-02-12: Tolerability of Adjuvant Abemaciclib in Older Adults with High-Risk Early Breast Cancer: Multicentre UK Real-World Data from the CONCISE Study
2026
·
H. Abdallah
, O. Ayodele
, et al.
·
Clinical Cancer Research
Abstract PS3-07-12: The CONCISE Study : A Pan-UK Real-World Audit of Adjuvant Abemaciclib Use in High-Risk Early Breast Cancer
2026
·
B. Baraka
, A. Ghose
, et al.
·
Clinical Cancer Research
568. the Prognostic Effect of Pathological Lymph Node Regression After Neoadjuvant Chemotherapy for Oesophageal Adenocarcinoma – a Multicentre Study
2022
·
Jonathan Moore
, Michael Green
, et al.
·
Diseases of the Esophagus
PDF
Hypoxia gene expression defines a poor prognostic sub-group in oesophageal adenocarcinoma
2018
·
R.V. Douglas
, C. McKinney
, et al.
·
Annals of Oncology
Association of a DNA damage response deficiency (DDRD) assay with prognosis in resected esophageal and gastric adenocarcinoma.
2017
·
Richard C. Turkington
, Laura A Knight
, et al.
·
Journal of Clinical Oncology
Targeting Akt in oesophageal adenocarcinoma
2016
·
L. Stevenson
, L. Cairns
, et al.
·
European Journal of Cancer
Pathways of Cisplatin Resistance in Oesophageal Adenocarcinoma.
2016
·
Richard Turkington
, Rosalie Douglas
, et al.
26 Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation
2013
·
R. Douglas
, L. Campbell
, et al.
·
Lung Cancer
Show more works
View as search
Works count:
21
Citation count:
91
H-index:
4
I10-index:
2
Year
Topic
Type